Meeting Banner
Abstract #1528

Early biomarkers of response to neoadjuvant chemotherapy in lung cancer: preliminary data from a multicenter international study

Dominic Carlin1,2, Alexander Weller1,2, Joost Kuijer3, Gerbrand M Kramer3, Arturo Chiti4, Mary E. R. O'Brien5, Sanjay Popat5, Yan Liu6, and Nandita M deSouza1,2

1CRUK Imaging Centre, Institute of Cancer Research, London, United Kingdom, 2MRI Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, 3VU University Medical Center, Amsterdam, Netherlands, 4Humanitas University, Milan, Italy, 5The Lung Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, 6European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium

Whole tumor ADC histogram parameters were assessed as early response biomarkers to platinum-based neo-adjuvant chemotherapy in 14 patients with non small cell lung cancer. On completion of treatment, 3 of 11 patients with DW-MRI at baseline and day 14 were classed responders by RECIST criteria. At Day 14 of treatment, there was a significant reduction in ADC metrics in responders (2 of 3 beyond limits of agreement) compared to non-responders (2 of 11 beyond limits of agreement). An increase in ADC 75th centile (indicating more voxels with higher ADC values), was consistent with necrosis; non-responders did not show this change.

This abstract and the presentation materials are available to members only; a login is required.

Join Here